Outcomes4Me – a developer of the leading direct-to-patient and AI-based platform transforming the cancer care experience – announced the closing of a $21 million funding round. With this round, Outcomes4Me welcomes a new investor, London-based Salica Investments, alongside all existing investors: Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD. This brings Outcomes4Me’s total capital raised to date to $38 million.
AI at the Center of Cancer Care: Outcomes4Me’s AI-based platform integrates real-time clinical guidelines, genomic insights, medication and symptom tracking, clinical trial matching, and patient peer communities into a single, easy-to-use interface for patients with cancer.
By combining AI with deep oncology expertise and generating new multimodal patient-level data enriched at the drug level, Outcomes4Me is uniquely positioned to accelerate the pace of innovation in cancer care, driving both improved patient outcomes and sustainable revenue growth.
Momentum: Outcomes4Me’s business is focused on advancing innovation and improving outcomes by partnering with life sciences companies to help them reach the right patient at the right time with the right action. And since its commercial launch in 2022, the company has been on an incredible revenue growth trajectory, reflecting the increasing demand for more innovative, more personalized cancer-care solutions. Notably, 7 out of the top 10 global cancer pharmaceutical companies are already among Outcomes4Me’s valued customers, further demonstrating its market leadership.
As part of its trajectory to become the leading global digital health solution for cancer care, Outcomes4Me is making strategic moves to expand internationally, to make a profound impact on global cancer care standards.
How the funding will be used: With this new funding, Outcomes4Me will:
1.) Accelerate its market penetration across a broader range of cancer types, geographies, and global markets
2.) Utilize its proprietary datasets and expand its AI capabilities to drive even more precise, real-time personalized treatment recommendations
3.) Scale its collaborations with top-tier health systems and life sciences companies globally
4.) Scale its revenue streams through new partnerships, international expansion, and innovative business models
5.) Drive outcomes-based evidence generation and real-world data insights for improved treatment and care
KEY QUOTES:
“AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale. With more than 280,000 cancer patients using our AI-enabled platform, we’re not just offering people diagnosed with cancer a tool, we’re empowering them with intelligent, real-time insights that guide them through every step of their care. This funding will help us further enhance our platform, expand our reach, and drive meaningful revenue growth.”
Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me
“Outcomes4Me is an AI-driven pioneer in the oncology space, scaling rapidly in a market that demands smarter, personalized healthcare solutions. We are excited to support their digital platform as part of our deep commitment to help advance oncology care and improve patient outcomes.”
Amy Summy, Executive Vice President, Chief Marketing Officer and Consumer Lead for Labcorp
